Memphasys Limited.
MEM.ASXHealth Care
Memphasys Limited (ASX:MEM) specialises in biological separations for commercial applications. The Company's patented membrane processes enable the selection of high value substances or contaminants from the fluid in which they are contained.
Market Data
$0.005
+0.2%$14.2M
-100000.0x
$-0.001
0.00%
-0.1%
Latest Earnings
Appendix 4D - Half-year Financial Report - 31 December 2025
27 February 2026
Memphasys Limited (ASX: MEM) reported its first meaningful commercial revenues for the half-year ended 31 December 2025, with invoiced revenue of just A$12,406 representing 235% growth from a negligible base, as the Felix™ sperm separation system commenced commercial rollout across Europe, MENA, Japan, and India. The net loss after tax improved 21% to A$2.34M (from A$2.97M pcp), aided by the absence of a A$896K impairment charge and reduced R&D spend, though one-off restructuring and legal costs weighed on the period. The company holds A$411K in cash, expects average monthly burn of ~A$250K going forward, and has A$94K in contract liabilities (orders received but not yet shipped) scheduled for fulfilment in Q1 CY2026. Key points: First commercial revenues recognised — A$12,406 invoiced in HY1 FY26, representing 235% growth from a near-zero base, with A$94K in additional orders on hand as contract liabilities at period end.; Net loss improved 21% to A$2.34M (pcp: A$2.97M), driven by a A$896K impairment absence and A$457K reduction in R&D expenditure.; Annualised operating costs reduced by ~39% following a strategic restructure, with monthly cash burn guided to ~A$250K from Q3 FY26 onward.
Recent Announcements
Appendix 4D - Half-year Financial Report - 31 December 2025
Memphasys Limited (ASX: MEM) reported its first meaningful commercial revenues for the half-year ended 31 December 2025, with invoiced revenue of just A$12,406 representing 235% growth from a negligible base, as the Felix™ sperm separation system commenced commercial rollout across Europe, MENA, Japan, and India. The net loss after tax improved 21% to A$2.34M (from A$2.97M pcp), aided by the absence of a A$896K impairment charge and reduced R&D spend, though one-off restructuring and legal costs weighed on the period. The company holds A$411K in cash, expects average monthly burn of ~A$250K going forward, and has A$94K in contract liabilities (orders received but not yet shipped) scheduled for fulfilment in Q1 CY2026. Key points: First commercial revenues recognised — A$12,406 invoiced in HY1 FY26, representing 235% growth from a near-zero base, with A$94K in additional orders on hand as contract liabilities at period end.; Net loss improved 21% to A$2.34M (pcp: A$2.97M), driven by a A$896K impairment absence and A$457K reduction in R&D expenditure.; Annualised operating costs reduced by ~39% following a strategic restructure, with monthly cash burn guided to ~A$250K from Q3 FY26 onward.
Get real-time alerts for MEM
Receive AI-powered earnings summaries and instant notifications when Memphasys Limited. releases results.
Register Free